Dr. Regan is the inventor of the company’s automated pathogen detection analyzer, MiQLab™. Before founding LexaGene, he led a team of scientists at Bio-Rad Laboratories in developing tests for detecting pathogens, cancer, and neurological disorders using droplet digital PCR. Prior to Bio-Rad, Jack helped QuantaLife, a startup company, bring its product from concept to commercialization where it was subsequently acquired by Bio-Rad. He has also worked at Applied Biosystems/Life Technologies on automated sample preparation and did his post-doctoral training at Lawrence Livermore National Laboratory, where he developed automated instruments to detect respiratory pathogens and bio-threat agents for the US government’s BioWatch program. His doctoral training at the University of California San Francisco focused on influenza viral replication.
Mr. Rebeck has over 20 years of capital market experience and an established international financial network. Mr. Rebeck was a Vice President and Senior Investment Advisor with Canada’s largest independent investment bank, Canaccord Genuity, where he was responsible for raising significant risk capital for growth companies, with a particular focus on natural resources and medical technology. Daryl has since worked to provide management expertise and grow shareholder value for organizations he has worked with. He served as Senior VP of Corporate Finance of NYSE-listed Auryn Resources, a $250 million market cap mining exploration company. Previous to this, Mr. Rebeck was a consultant of corporate finance with Cayden Resources Inc., which was sold to Agnico Eagle Mining Limited for $205 million in November 2014.
Mr. Mitchell has over two decades of financial and SEC experience. Before joining LexaGene, he served in positions of increasing responsibility including Controller and Director of Finance, overseeing areas such as public company financial reporting, audits, and financial planning and analysis for Palomar Medical Technologies, Inc. which was publicly traded on the NASDAQ before Jeff helped orchestrate its sale to Cynosure in 2013 for $294 million. In addition to his many years at Palomar, Mr. Mitchell has served in numerous financial and strategic advisory roles for medical device, imaging, and diagnostic companies.
Dr. Walsh has over 20 years experience interfacing between biology and bioinformatics. His experience with DNA sequence projects includes primer design, next-generation sequencing (NGS), cancer detection, microarrays, and pathway identification. Dr. Walsh most recently served as Head of Informatics at Bio-Rad's Digital Biology Center of Cambridge building a rapid-result next-generation sequencer; prior to that, he served as Senior Director of Informatics and IT to create drug hits from DNA encoded libraries. Dr. Walsh has been a post-doctoral fellow at Harvard Medical School with George Church and Brigham and Women's Hospital Department of Genetics. He has a Biochemistry degree from Brown University and a Ph.D. in Biology from MIT.
Mr. Armstrong has spent his career leading numerous teams in the commercialization of complex medical devices, directly overseeing global operations including design, development, manufacturing, and service operations in eight countries. Throughout his career, he has been responsible for obtaining FDA and global regulatory approvals in over 100 countries for more than 50 devices with hundreds of indications, implementing best-in-class quality management systems, and ensuring worldwide compliance. Mr. Armstrong started his career involved with the development and launch of LASIK technology and has brought new laser and light-based technologies to a variety of medical specialties over the past 25 years for organizations including Palomar Medical Technologies and IPG Medical in both human clinical and veterinary technologies.
Dr. Nair has over 7 years of experience developing and leading teams in the development of molecular diagnostic and pathogen typing assays in compliance with FDA IVD regulations for clinical diagnostics and AOAC guidelines for food safety applications. Before joining LexaGene, Dr. Nair served as Staff Scientist at Beckman Coulter Molecular Diagnostics and Senior Scientist at Roche Molecular Systems, where he helped the development of various qualitative and quantitative diagnostic assays for 510(k) clearance, PMA and CLIA waiver. Dr. Nair is also a trained veterinarian and specialized in the diagnosis and treatment of animal diseases in his early career. Dr. Nair conducted his postdoctoral studies at the University of Pennsylvania and Albany Medical College, concentrating on host-pathogen interactions in infections caused by bio-threat agents. His doctoral training at the University of Connecticut focused on the molecular pathogenesis of Cronobacter sakazakii and its detection in contaminated infant formula.
Dr. Kolossovski is a seasoned product strategist and marketer with a decade of experience in diagnostics and life sciences. Over the years, she has held multiple sales and marketing positions of increasing responsibility with companies in the clinical diagnostics space such as BD (Becton, Dickinson and Company), Roche, and Qiagen. She has a successful track record of leading new product development from concept to launch, creating and implementing effective marketing plans, and delivering sustainable revenue and profitability growth across the instruments, reagents, and services continuum. Most recently, she was Senior Global Product Manager at Qiagen, where she led the worldwide launch of kits for genetic analysis and a portable qPCR cycler with a particular focus on the public health and applied testing market segments. A molecular biologist by training, Dr. Kolossovski received her PhD from the Australian National University and completed an Executive MBA from the Australian Graduate School of Management.